Nichols KK, et al. - This OPUS-3 trial aimed to assess the ocular comfort of lifitegrast ophthalmic solution 5.0% in the patients with dry eye disease (DED). Findings demonstrated that lifitegras was well tolerated and the drop comfort scores reached placebo levels by 3 minutes postinstillation.